Cannabis for the Prophylactic Treatment of Migraine (NCT03972124)
Cannabis for the Prophylactic Treatment of Migraine: a Randomized Double-Blind Placebo-Controlled Clinical Trial
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (18 items).
Location: CHAMP Research (Calgary Headache Assessment & Management Program) — Calgary, Alberta
Age range: 25 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Other active primary headaches, such as cluster headache, hemicrania continua, etc.
- Any secondary headache, such as headache related to intracranial hypertension, intracranial hypotension, hydrocephalus, intracranial mass lesion, etc.
- Pregnant, planning to become pregnant, or breastfeeding.
- Active or significant history of major mental illness, including severe depression, or anxiety, and any history of psychosis or schizophrenia.
- History of or current substance use disorder.
- Regular use of cannabis for medical or recreational reasons during the previous 12 months.
- History of significant cardiovascular or cerebrovascular disease, such as previous myocardial infarction, stroke, or peripheral vascular disease.
- History of hypertension greater than 160/100 and not medically treated.
- Any past history of seizure disorder.
- Liver disease or liver enzymes two or more times the upper limit of normal at baseline.
- Severe renal disease or GFR more than 30% below expected.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- CHAMP Research (Calgary Headache Assessment & Management Program) — Calgary, Alberta
📞 Contact the Study Coordinator
Phone: 403-956-3427 or 403-956-3548
Email: champ.research@ucalgary.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Migraine
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults — Birmingham, Alabama
- Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial — Vancouver, British Columbia
- BOTOX® vs. XEOMIN® for Chronic Migraine — Jacksonville, North Carolina
- Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo) — Ann Arbor, Michigan
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Huntsville, Alabama
Explore by condition: All Chronic Migraine clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.